XTL BIOPHARMACEUTICALS LTD

For the period ended Dec 31, 2024. Filed Apr 30, 2025.

View on SEC.gov

About this filing

The yearly report of a company based outside the US. It covers much of what a 10-K does, and may follow accounting rules other than US ones.

FY2024 · Filed Apr 30, 2025

XTLB$1.55-9.4%Stored close · as of Nov 6, 2026

See the whole filing, with its images and exhibits

Contents

Cover page SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS

PART I

ITEM 1. Identity of Directors, Senior Management and Advisers (no text here)

ITEM 2. Offer Statistics and Expected Timetable (no text here)

ITEM 3. Key Information ITEM 4. Information on the Company ITEM 4A. Unresolved Staff Comments ITEM 5. Operating and Financial Review and Prospects ITEM 6. Directors, Senior Management and Employees ITEM 7. Major Shareholders and Related Party Transactions ITEM 8. Financial Information ITEM 9. The Offer and Listing ITEM 10. Additional Information ITEM 11. Quantitative and Qualitative Disclosures About Market Risk

ITEM 12. Description of Securities other than Equity Securities (no text here)

PART II

ITEM 13. Defaults, Dividend Arrearages and Delinquencies (no text here)

ITEM 14. Material Modifications to the Rights of Security Holders and Use of Proceeds (no text here)

ITEM 15. Controls and Procedures

ITEM 16. Reserved (no text here)

ITEM 16A. Audit Committee Financial Expert ITEM 16B. Code of Ethics ITEM 16C. Principal Accountant Fees And Services

ITEM 16D. Exemptions From The Listing Standards For Audit Committees (no text here)

ITEM 16E. Purchases Of Equity Securities By The Issuer And Affiliated Purchasers

ITEM 16F. Change In Registrant’s Registered Accountant (no text here)

ITEM 16G. Corporate Governance

ITEM 16H. Mine Safety Disclosure (no text here)

ITEM 16I. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections (no text here)

ITEM 16J. Insider Trading Policy ITEM 16K. Cybersecurity Item 8. Report of Independent Registered Public Accounting Firm Statements of Financial Position Statements of Comprehensive Income (Loss)Statements of Changes in Equity Statements of Cash Flows Notes to Consolidated Financial Statements ITEM 19. Exhibits SIGNATURES

ITEM 16B. Code of Ethics

We have adopted a Code of Conduct applicable to all directors and officers of our company, including our principal executive officer, principal financial officer, principal accounting officer or controller and other individuals performing similar functions. A copy of our Code of Conduct can be found on our website (http://www.xtlbio.com) and may also be obtained, without charge, upon a written request addressed to our investor relations department, XTL Biopharmaceuticals Ltd., 26 Ben-Gurion St., Ramat Gan 5112001, Israel.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.